US Bancorp
NAGE

US Bancorp’s Niagen Bioscience NAGE Stock Holding History

US Bancorp’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-148
Closed -$653 – 4380
2026
Q1 		$653 Hold
148
– – ﹤0.01% 3978
2025
Q4 		$941 Sell
148
-36
-20% -$250 ﹤0.01% 3861
2025
Q3 		$1.72K Buy
184
+15
+9% +$151 ﹤0.01% 3774
2025
Q2 		$2.44K Buy
169
+148
+705% +$1.46K ﹤0.01% 3827
2025
Q1 		$145 Buy
+21
New +$132 ﹤0.01% 4119
2017
Q1 		– Sell
-22,634
Closed -$75K – 3652
2016
Q4 		$75K Hold
22,634
– – ﹤0.01% 2250
2016
Q3 		$67K Buy
+22,634
New +$83.1K ﹤0.01% 2291

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

US Bancorp's NAGE Position: Q2 2026 in Review

US Bancorp sold out of Niagen Bioscience (NAGE) in Q2 2026, closing a stake of 148 shares — an estimated $653 sold.

US Bancorp first reported a position in NAGE in Q3 2016 and held it in 7 quarters. The position peaked at $75K in Q4 2016. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • US Bancorp reported no remaining Niagen Bioscience position as of Q2 2026 after selling out during the quarter.
  • US Bancorp sold 148 Niagen Bioscience shares in Q2 2026, an estimated $653.
  • US Bancorp first reported a position in Niagen Bioscience in Q3 2016 and held it in 7 quarters.
  • US Bancorp's Niagen Bioscience position peaked at $75K in Q4 2016.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.